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Abstract
Strategies to enhance the relaxometric properties of gadolinium (Gd)-based contrast agents (CAs) for magnetic resonance
imaging (MRI), without the chemical modification of chelates, have recently had a strong impact on the diagnostic field. We have
taken advantage of the interaction between Gadolinium diethylenetriamine penta-acetic acid (Gd-DTPA) and the hydrogel
structure of hyaluronic acid to design cross-linked hyaluronic acid nanoparticles down to 35 nm for use in MRI applications. The
proposed bioformulations enable the control of the relaxometric properties of CAs, thus boosting the relaxation rate of T1. Our
results led us to identify this approach as an adjustable scenario to design intravascularly injectable hydrogel nanoparticles
entrapping Gd-DTPA. This approach overcomes the general drawbacks of clinically approved CAs having poor relaxivity and
toxic effects.
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Our work1 entitled “A Microfluidic Platform to Design Cross-
linked Hyaluronic Acid Nanoparticles (cHANPs) for Enhanced
MRI,” recently published by Scientific Reports, exploits a
microfluidic flow-focusing approach to synthesize hydrogel
nanoparticles down to 35 nm. This method provides a rational
entrapment of the gadolinium-DTPA (Gd-DTPA) for magnetic
resonance imaging (MRI) boosting its relaxometric properties.
Furthermore, systems with monodisperse size under 100 nm
are likely to improve delivery functions to the tissues, stability
of the metal chelates, and also provide enhanced relaxometric
properties of the Gd-based contrast agents (GBCAs; Figure 1).
Gadolinium-DTPA has been selected because of its daily use in
the clinical practice.
Contrast agents (CAs) are paramagnetic metal ions able to
enhance the contrast in MR images by positively influencing the
relaxation rates of water protons in the immediate surroundings
of the tissue in which they localize. Among different CAs,
GBCAs are routinely used in the clinical MRI practice.
Magnetic resonance imaging represents the first-line diagnostic
imaging modality for numerous indications. Gadolinium-based
CAs are injected before the examination. This permits the detec-
tion of various pathologic processes otherwise not appreciable
without an enhancedMR or other imaging modalities. The wide-
spread use of GBCAs still has several limitations, such as low
efficacy, toxic effects, and lack of tissue specificity. Indeed, their
relaxivity is still far away from the theoretical limits, and they
still present nephrotoxicity and heavy allergic effects. Further-
more, recent studies conducted by Kanda et al2 and McDonald
et al 3-5 reported the risk of intracranial deposition of elemental
Gd in neuronal tissues after GBCAs administration, even after
only 1 MRI scan. Patients with normal renal and hepatobiliary
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function were also at risk. The authors pointed out that the
clinical significance of these findings is not completely under-
stood at this time. In the meantime, the Food and Drug Admin-
istration alarmed the medical community about the risk of
deposition, recommending health-care professionals to limit the
use of GBCAs unless necessary. This warning could have a
potential negative impact on the early diagnosis of several
pathologies (www.FDA.GOV.com/safety announcement 7-27-
2015). With this in mind, the ability to provide a formulation
able to overcome several of these limitations is of great interest
to the scientific and the medical community. It is essential to
highlight the need to not only build a new system but also build a
biocompatible probe with higher relaxivity. This probe should
be able to protect the chelate around Gd ions from transmetalla-
tion phenomena and control the accumulation and the clearance
of the GBCAs in a specific organ.
In the last few years, many efforts have been made to
develop better CAs based on nanostructures with higher relax-
ivity and lower toxicity. Compared to other strategies based on
bioconjugation or encapsulation6, models made on the optimi-
zation of “rigidification”7 and “confinement”8 of metal che-
lates seem to be the most effective at enhancing the effect of
GBCAs without the chemical modification of the chelate9.
Recently, we have also explored the impact in the bulk of
cross-linked and uncross-linked biopolymer matrices on
relaxometric properties of CAs. We found the contribution to
the enhancement of CAs is highlighted and attributed to the
reduced mobility of water within the hydrogel.10
Although there has been a growth of interest in the imaging
field and significant efforts have been made to apply micro-
fluidic technologies to the production of nanoparticles,11 the
exploitation of microfluidic approaches to support the design of
hydrogel nanostructures for MRI is still lacking. Microfluidics
is an interdisciplinary field of research combining soft matter
physics, biochemistry, and microsystems engineering. It
enables the accurate control of fluids and constant manipula-
tion of individual process parameters and phenomena, such as
mixing, flow rate, chemical reaction, and phase separation
behavior.12 However, impacting the relaxometric properties
of CAs without chemically modifying chelates has yet to be
studied by modulating the properties of nanoparticles with con-
trolled nanoprecipitation in a microfluidic flow-focusing
system.6 This method could be used to obtain a new class of
MRI approaches based on rational polymer nanostructures.
Our study has reported, for the first time, interferences of
the Gd chelate in the flow-focusing approach that could sig-
nificantly advance the core knowledge of the interaction
between Gd chelates and hydrogel matrix to be applied to
MRI. The use of microfluidics allowed us to observe this
phenomenon and allowed for the setting up of a flow-
focusing strategy to modulate the nanoprecipitation playing
on the hydrophilic–lipophilic properties of the surfactants and
modulate the pH levels to optimize relaxometric perfor-
mances of the MRI CAs.
The simultaneous addition to the middle channel of Gd
together with HA solution causes significant interference on
the flow-focusing pattern and consequently affects nanoparti-
cle shape, size, and encapsulation. Process parameters were
controlled to obtain monodisperse nanoparticles and improved
properties of the Gd-DTPA entrapped within our nanoparticles.
Cross-linked hyaluronic acid nanoparticles are produced using
divinyl sulfone (DVS) as a cross-linking agent. The HA-DVS
biocompatibility has been already confirmed by histological
analysis, as previously reported by Oh et al.13 The cross-
linking reaction occurs simultaneously with the nanoprecipita-
tion. This increases cHANPs’ stability in water and avoids
swelling. Above all, it is essential in controlling degradation,
release properties, and allows retainment of Gd-DTPA.
Given the versatility of our cHANPs, it was particularly inter-
esting to investigate how the selection of different reaction stra-
tegies and formulations could result in advanced and tailorable
CA-loading functionalities. Gd-DTPA entrapped cHANPs have
the capability to retainGBCAs to boost theMRsignalwithout the
chemical modification of the chelates and at the same time could
potentially provide tissue specificity and reduce nephrotoxicity
and intracranial Gd deposition. In vitro relaxivity has been
studied for loaded and unloaded cHANPs at 37C and 1.5
T by a relaxometric instruments. These results were com-
pared to the commercial CA: Magnevist. In our platform, by
fine-tuning the mixing of all species, nanoprecipitation
behavior and cross-linking reaction are adjusted very pre-
cisely and simultaneously, leading to relaxivity values about
12 times larger than that of free CAs clinically available.
We propose a microfluidic platform along with our efficient,
straightforward, and scalable strategies to aid in the develop-
ment of intravascularly injectable and completely biocompati-
ble hydrogel nanoparticles, entrapping clinically approved CAs
for application in diagnostics and therapy. The strength of our
scientific work is that we have used and combined clinically
approved materials, such as HA and Gd-DTPA.
Figure 1. A proposed fashionable way to entrap gadolinium-DTPA
(Gd-DTPA) in cross-linked hyaluronic acid nanoparticles (cHANPs)
for application in diagnostics and therapy. The microfluidic flow-
focusing approach used to control the interference of gadolinium in
the nanoprecipitation phenomena and to design the nanoparticles is
reported. Beyond the significant improvements generated by the
utilization of the proposed microfluidic platform, the minimalist illus-
tration clearly presents the idea to set up a reduced time-consuming
process that is able to produce ready to use and completely bio-
compatible nanoparticles to impact immediately on the clinical
magnetic resonance imaging (MRI) applications.
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Our method allowed for strict control of nanoparticle char-
acteristics and the entrapment of the Gd-DTPA, resulting in a
low polydispersity of nanoparticles and a high encapsulation
efficiency of the metal in the nanoparticles, as well as easy
recovery of the obtained particles without long and expensive
purification steps. Additionally, this microfluidic approach
enabling the tuning of the physicochemical properties of the
obtained nanoparticulate architectures that have been proved to
boost the MRI signals.
The aim of this work was to contribute to the solution of the
physical and biological limits regarding the clinical use of CAs.
We have proved that it is possible to increase relaxivity by
tuning the structural parameters of hydrogel nanoparticles. At
the same time, we were also able to improve tissue specificity,
the stability of the chelates, imaging diagnostic acquisition, and
potentially reduce the administration dosage. The developed
microfluidic strategies allow for a fine-tuning of the formula-
tions that can easily be applied to different polymers and mate-
rials, or a combination of materials, involved in the
nanomedicine field. These developments will allow us to make
a library of customized nanostructures.
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